Bio-Rad Labs (BIO) Tops Q1 EPS by 30c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Bio-Rad Reports First-Quarter 2020 Financial Results
May 6, 2020 4:15 PM EDTHERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2020.
First-quarter 2020 net sales were $571.6 million, an increase of 3.2 percent compared to $554.0 million reported for the first quarter of 2019. On a currency-neutral basis, quarterly sales increased 4.3 percent compared to the same period in 2019. First-quarter gross margin was 55.5 percent compared to 56.3 percent during the first quarter in 2019.
Life Science segment net sales for the first quarter were $227.2 million, an increase of 5.3 percent compared to the... More
